Literature DB >> 28664285

[Psoriasis vs. psoriatic arthritis : Similarities and differences in the pathophysiology].

T Pap1, C Sunderkötter2.   

Abstract

Psoriasis is a chronic inflammatory skin disease with genetic and (auto)immunological backgrounds. Up to 30% of patients with psoriasis also develop a mostly oligoarticular arthritis with spinal involvement that is termed psoriatic arthritis (PsA) and shows a specific joint pattern which differs from that of rheumatoid arthritis (RA). Both Psa and psoriasis share a common main axis, the interleukin (IL) 23/IL17 pathway as well as major overlaps in the functions of tumor necrosis factor alpha (TNFalpha). Recently acquired knowledge supports the concept that in both diseases, similar genetic dispositions and molecular pathways lead to organ-specific disease patterns. In some types of PsA, genetic predisposition and the relevance of acute inflammatory reactions appear to be greater that in psoriasis, while in the latter exogenous factors and T‑lymphocyte reactions in the skin seem to have a higher impact. A key difference between PsA and cutaneous psoriasis is the largely irreversible nature of inflammatory joint changes in PsA, whereas cutaneous plaques in psoriasis completely heal. The question of how interdependent both diseases are and whether immunologically primed T‑lymphocytes from cutaneous lesions in PsA may transmit the disease to the synovial membranes and induce acute inflammation is not precisely known. A detailed analysis of these organ-specific differences may not only provide an explanation for the similar, but partly different efficacy of novel therapeutic strategies but may also lead to the development of personalized therapies that take into account the individually different manifestations of the diseases over time.

Entities:  

Keywords:  Immune response; Interleukin 17; Interleukin 23; Rheumatoid arthritis; Tumor necrosis factor alpha

Mesh:

Substances:

Year:  2017        PMID: 28664285     DOI: 10.1007/s00393-017-0342-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  19 in total

1.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Philip J Mease; Dafna D Gladman; Christopher T Ritchlin; Eric M Ruderman; Serge D Steinfeld; Ernest H S Choy; John T Sharp; Peter A Ory; Renee J Perdok; Mark A Weinberg
Journal:  Arthritis Rheum       Date:  2005-10

Review 2.  Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.

Authors:  Axel Patrice Villani; Marie Rouzaud; Morgane Sevrain; Thomas Barnetche; Carle Paul; Marie-Aleth Richard; Marie Beylot-Barry; Laurent Misery; Pascal Joly; Michel Le Maitre; Selim Aractingi; François Aubin; Alain Cantagrel; Jean-Paul Ortonne; Denis Jullien
Journal:  J Am Acad Dermatol       Date:  2015-06-06       Impact factor: 11.527

3.  Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation.

Authors:  Athanasios Stratis; Manolis Pasparakis; Rudolf A Rupec; Doreen Markur; Karin Hartmann; Karin Scharffetter-Kochanek; Thorsten Peters; Nico van Rooijen; Thomas Krieg; Ingo Haase
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

4.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.

Authors:  Andrea Chiricozzi; Emma Guttman-Yassky; Mayte Suárez-Fariñas; Kristine E Nograles; Suyan Tian; Irma Cardinale; Sergio Chimenti; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

5.  Ustekinumab associated with flares of psoriatic arthritis.

Authors:  Emily F Stamell; Allison Kutner; Kate Viola; Steven R Cohen
Journal:  JAMA Dermatol       Date:  2013-12       Impact factor: 10.282

6.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

7.  Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.

Authors:  John Bowes; Ashley Budu-Aggrey; Ulrike Huffmeier; Steffen Uebe; Kathryn Steel; Harry L Hebert; Chris Wallace; Jonathan Massey; Ian N Bruce; James Bluett; Marie Feletar; Ann W Morgan; Helena Marzo-Ortega; Gary Donohoe; Derek W Morris; Philip Helliwell; Anthony W Ryan; David Kane; Richard B Warren; Eleanor Korendowych; Gerd-Marie Alenius; Emiliano Giardina; Jonathan Packham; Ross McManus; Oliver FitzGerald; Neil McHugh; Matthew A Brown; Pauline Ho; Frank Behrens; Harald Burkhardt; Andre Reis; Anne Barton
Journal:  Nat Commun       Date:  2015-02-05       Impact factor: 14.919

8.  Doxycycline-induced expression of transgenic human tumor necrosis factor α in adult mice results in psoriasis-like arthritis.

Authors:  Eugen Retser; Tanja Schied; Boris V Skryabin; Thomas Vogl; Janos M Kanczler; Nina Hamann; Anja Niehoff; Sven Hermann; Michel Eisenblätter; Lydia Wachsmuth; Thomas Pap; Peter L E M van Lent; Karin Loser; Johannes Roth; Frank Zaucke; Stephan Ludwig; Viktor Wixler
Journal:  Arthritis Rheum       Date:  2013-09

9.  Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?

Authors:  Stefano Alivernini; Barbara Tolusso; Luca Petricca; Laura Bui; Gabriele Di Sante; Giusy Peluso; Roberta Benvenuto; Anna Laura Fedele; Franco Federico; Gianfranco Ferraccioli; Elisa Gremese
Journal:  Ann Rheum Dis       Date:  2017-01-24       Impact factor: 19.103

10.  Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.

Authors:  Edmund Lee; William L Trepicchio; Judith L Oestreicher; Debra Pittman; Frank Wang; Francesca Chamian; Madhav Dhodapkar; James G Krueger
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.